Cancer

Mendel.AI

Mendel.ai automates matching cancer patients to clinical trials through personal medical history and genetic analysis. This company aims to enable healthcare organizations to learn from the journey of every patient at scale. They make this possible through a proprietary end-to-end AI platform, meticulously quality-controlled by a world-class team of trained clinical experts.

For more information, https://www.mendel.ai/

Cellworks

This company is a developer of a biosimulation platform, and has developed a biosimulation platform that uses computational modeling and offers the life science industry a framework for designing therapeutics to transform entirely empirical drug development. The platform is used for predicting responses to FDA-approved cancer therapies, & provides personalized cancer therapy recommendations.

For more information, https://cellworks.life/company/about

Artera AI

ArteraAI is a leading precision medicine company developing AI tests to personalize cancer therapy. ArteraAI offers an AI-enabled test that is the first of its kind to provide both predictive and prognostic results for patients with localized prostate cancer. This company utilises digital pathology images and clinical data, creating a testing method that can predict therapy benefit and determine prognosis for a patient. Rather than focusing on one clinical attribute, the AI analyzes multiple characteristics of the individual patient and accomplishes things that conventional techniques and computers cannot do alone.

For more information, https://artera.ai/our-company

Lucence

A biotech company that is developing blood testing technologies to help detect cancer in an early stage. Their featured product, LucenceINSIGHT™, uses proprietary amplicon-based next-generation sequencing technology to screen for the signal of 10 cancers with a sensitivity of 71.4% and specificity of 99.2%. When a cancer-associated finding is made, the machine-learning algorithm analyzes the data to predict the tumor of origin, alerting them as ‘areas of concern’ with an accuracy of 90%. This system can detect breast, lung, colorectal, nose, liver, pancreas, prostate, bile duct, Acute Myeloid Leukemia (AML) and Chronic Lymphoid Leukemia (CML) cancers.

For more information, https://www.lucence.com/